title: The business case for cell and gene therapies.
authors.affiliation: 1] Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine, Campus Virchow, Berlin, Germany. [2] Department of Nephrology and Internal Intensive Care, Charité University Medicine, Campus Virchow, Berlin, Germany.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abou-El-Enein
authors.affiliation: University of California, Davis, Institute For Regenerative Cures, Sacramento, California, USA.
authors.forename: Gerhard
authors.initials: G
authors.lastname: Bauer
authors.affiliation: 1] Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine, Campus Virchow, Berlin, Germany. [2] Department of Nephrology and Internal Intensive Care, Charité University Medicine, Campus Virchow, Berlin, Germany.
authors.forename: Petra
authors.initials: P
authors.lastname: Reinke
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D015316:Genetic Therapy / Q000191:economics*; D006801:Humans